spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Dysport 

 HSMN NewsFeed - 14 Sep 2023
Galderma Launches Advanced New Serum with Alastin Skincare(R) - C-Radical Defense Antioxidant Serum
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Oct 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2018
Galderma Announces FDA Approval of Restylane(R) Lyft For Midface Injection via Cannula
Devices Dermatology FDA
 HSMN NewsFeed - 24 Mar 2017
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 12 Dec 2016
Galderma Announces FDA Approval of Restylane(R) Refyne and Restylane(R) Defyne Dermal Fillers for Treatment of "Laugh Lines"
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 1 Aug 2016
Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2016
Ipsen Announces FDA Approval of Dysport(R) (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jul 2016
David Meek appointed as Chief Executive Officer of Ipsen
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Feb 2016
Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2016
Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and Canada
Biopharmaceuticals Devices Dermatology Personnel
 HSMN NewsFeed - 2 Jul 2015
Galderma Receives FDA Approval to Market Restylane(R) Lyft with Lidocaine to Correct Age Related Volume Loss in the Cheek Area
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Jul 2014
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Biopharmaceuticals Dermatology Distribution
 HSMN NewsFeed - 5 Feb 2014
Ipsen announces clinical results of Dysport(R) Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW(1)
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2014
Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America
Biopharmaceuticals Neurology Distribution
 HSMN NewsFeed - 23 Oct 2013
FDA Approves JUVÉDERM VOLUMA(TM) XC
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Jun 2013
Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become Profitable in the US in 2014
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Nov 2012
Valeant Pharmaceuticals Announces New Management Appointments
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 20 Nov 2012
Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 25 Apr 2012
Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ)
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 28 Sep 2011
Graceway Pharmaceuticals, LLC Reaches Agreement to Sell its Assets to Galderma S.A.
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 30 Aug 2011
Appointments to Ipsen’s Executive Committee: Nathalie Joannes is nominated Executive Vice President, General Counsel and Susheel Surpal is nominated Executive Vice President, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2010
Ipsen: Encouraging results of GuidAge(R), large scale European trial conducted in the prevention of Alzheimer's Dementia
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jun 2010
Medicis Announces Organizational Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2010
Medicis Receives Approval for RESTYLANE(R) and PERLANE(R) With Lidocaine
Devices Dermatology FDA
 HSMN NewsFeed - 29 Oct 2009
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2009
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 26 Jun 2009
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 30 Apr 2009
FDA Approves Dysport(TM) for Therapeutic and Aesthetic Uses
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2009
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 12 Mar 2009
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 2 Feb 2009
The Health Authorities of 15 European Countries Give a Collective Green Light to Azzalure For the Treatment of Glabellar Lines, Paving the Way for National Marketing Authorizations
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 10 Mar 2008
ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Mar 2008
Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 26 Feb 2008
CollaGenex Pharmaceuticals Signs Merger Agreement with Galderma Pharma S.A.
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 26 Feb 2008
Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 31 Jan 2008
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport(R) in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
Biopharmaceuticals Distribution Dermatology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Dysport
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.